Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 6, 2019
USP’s Generics Access Plan to Encourage Competition
Author(s)Pharmaceutical Technology Editors
The US Pharmacopeial Convention’s new plan will include new and revised quality standards and activities to support the development of new generic drugs.
Advertisement
On Jan. 31, 2019, the US Pharmacopeial Convention (USP)
The new plan will include the development and updating of quality standards, training and education for generic-drug manufacturers on best practices for applying quality standards, and working with industry groups and regulators to identify ways to support generic-drug development.
“Millions of Americans have benefitted from generic medicines and in just the last 10 years $1.5 trillion have been saved, yet there are still many off-patent medications that have few or no generic alternatives,” said Ronald T. Piervincenzi, PhD, USP chief executive officer, in a press release. “While there has been much progress, there are still many off-patent drugs that have limited or no generic options. We must close this gap, which is why USP is committed to doing our part by developing new public standards and processes, working with the FDA and others to facilitate greater access to important drug therapies.”
USP quality standards, requirements, testing methods, and quality expectations are available for generic-drug manufacturers worldwide to ensure the quality of drugs. “Manufacturers can rely on USP quality standards, helping accelerate availability of generic versions of off-patent medicines,” said Piervincenzi. “This helps provide patients more access to affordable alternatives of the medicines they need.”
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement